Since the disaster at the Fukushima No. 1 nuclear power plant in March 2011, people became concerned about adverse eŠects of radiation, in particular those of low dose radiation strongly. The eŠects of radiation on chromosome DNA are stochastic events, and thus it is thought that radiation poses cancer risk to humans even at very low doses. Likewise, genotoxic compounds, which interact with DNA and induce mutations, are assumed to have no thresholds for their action. These compounds are used to be called``radiomimetic compounds''. Hence, genotoxic carcinogens, which induce cancer via genotoxic mechanisms such as mutations, are regulated based on a paradigm that they have no thresholds for the cancer risk. Recently, however, the paradigm has been challenged by research on analyzes of carcinogenicity and genotoxicity of chemicals at low doses. In addition, organisms including humans possess various self-defense mechanisms, such as detoxication metabolism, DNA repair, error-free translesion DNA synthesis and apoptosis etc, which may suppress genotoxicity of chemicals at low doses and reduce the mutation frequency and cancer risk to spontaneous levels. These self defense mechanisms may constitute``apparent'' or``practical'' thresholds for genotoxic carcinogens. To discuss the low dose eŠects of genotoxic and carcinogenic compounds and the implication in regulatory toxicology, the second international symposium on genotoxic and carcinogenic thresholds was held on November 23, 2011 in Tokyo. In this symposium, six and four experts of genotoxicity and chemical carcinogenicity were invited from inside and outside of Japan, respectively, to discuss genotoxicity and carcinogenicity of chemicals at low doses and the regulatory policies. This symposium follows the precedent symposia``International symposium-threshold of carcinogenicity and genotoxicity'' in Kobe in Japan in 2006, and``the 1st International symposium on genotoxic and carcinogenic thresholds'' in Tokyo in 2008. Here, we summarize the presentations of the symposium to discuss future perspectives of research on genotoxic and carcinogenic thresholds.
Session 1 (Chaired by Shoji Fukushima and Samuel M. Cohen)

Opening Address
Takehiko Nohmi (National Institute of Health Sciences)
Nohmi declared the opening of the symposium and introduced basic concepts of regulation for chemical carcinogens. Currently, carcinogens are classiˆed into genotoxic and non-genotoxic carcinogens. Genotoxic carcinogens are those that induce cancer through interaction with DNA and induction of mutations. Typical examples are a‰atoxin B1 and dimethylnitrosamine. These compounds are positive in Ames Salmonella mutation assays and have structural alerts, e.g., epoxides, aromatic amino groups or nitroso groups, which are characteristics of DNA-interacting agents. They induce tumors in multiple organs of trans-species of rodents. Non-genotoxic carcinogens induce cancer through mechanisms other than DNA interactions or mutations. The mechanisms include cytotoxicity, hormonal eŠects and in‰ammation. Non-genotoxic carcinogens usually induce tumors in single organs in single species of rodents. The classiˆcation of carcinogens into genotoxic or non-genotoxic ones is important in administrative regulation because genotoxic carcinogens are regulated based on the assumption that they have no thresholds for cancer risk. Therefore, no acceptable daily intake (ADI) can be set for genotoxic carcinogens. In contrast, non-genotoxic carcinogens are regulated as other toxic compounds that they have thresholds for the action. Non-genotoxic carcinogens can be used safety below the threshold dose while genotoxic carcinogens impose cancer risk to humans even at very low doses. Nohmi ques-* ED 001 : the eŠective dose of carcinogen that induces 10 excess tumors in 10,000 animals. ** LED 10 : a lower conˆdence limit on dose estimate of carcinogen that achieves 10z incidence of tumors. tioned the assumption because humans possess multiple defense mechanisms, e.g., detoxication, DNA repair, error-free translesion DNA synthesis and apoptosis, which may suppress the cancer risk to spontaneous levels and constitute``practical'' thresholds for genotoxic carcinogens. He emphasized the importance of understanding the mechanisms underlying the practical thresholds to solve the issue of genotoxic and carcinogens thresholds.
Genotoxic Thresholds: Identiˆcation of Mutations in vivo and Mechanistic Studies in vitro
Takehiko Nohmi (National Institute of Health Sciences, Japan) First, Nohmi reported characteristics of gpt delta transgenic mice and rats for in vivo gene mutation assays. These transgenic rodents allow to detect mutagenicity of chemicals in any organs of rodents such as liver, stomach and testis. In addition, mutations can be identied at sequence levels. The transgenic rodents have been established in genetic backgrounds of C57BL/6J mice, Sprague-Dawley rats and Fischer 344 rats. At present, Ames Salmonella mutation assay is the most widely employed mutation assay and Ames positive compounds are interpreted as mutagenic compounds. However, there are cases where the results of Ames assay are inconsistent with those of cancer bioassays with rodents. Nohmi proposed that in vivo mutation assays with gpt delta transgenic mice may provide more reliable information whether the chemical is genotoxic or not because the in vivo assays can detect mutations in target organs of carcinogens. Second, Nohmi reported novel human cell lines expressing genetically modiˆed specialized DNA polymerases, i.e., DNA polymerases z and k, and showed results suggesting that error-free translesion DNA synthesis catalyzed by the polymerases might be a factor in‰uencing the practical thresholds for genotoxicity of chemicals. He also introduced an endeavor to introduce single DNA adduct, i.e., 8-oxo-7,8-dihydro-2?deoxyguanosine (8-oxo-dG), into a speciˆc site of human chromosome. The results suggest that not all 8oxo-dG formed in the chromosome induces mutations in human cells.
Threshold of Genotoxic Carcinogens: It Is Central Concerns of Carcinogenic Risk Assessment
Shoji Fukushima (Japan Bioassay Research Center, Japan) Dr. Fukushima reported low-dose carcinogenicity data based on medium-term rat liver bioassays for three genotoxic hepatocarcinogens. Although administration of 2-amino-3,8-dimethylimidazo[4,5-f ]quinoxaline (MeIQx) generated DNA-MeIQx adducts even at very low doses, higher doses are required to elevate levels of 8-hydroxy-2?-deoxyguanosine (8-OHdG) and frequencies of gene mutations. Induction of glutathione Stransferase placental form (GST-P) positive foci, a wellknown preneoplastic lesion in rat hepatocarcinogenesis, was observed only at the highest dose. Similarly, 2amino-3-methylimidazo[4,5-f ]quinoline (IQ) caused an increase in the number of GST-P positive foci only at high doses. Induction of p21 Cip/WAF1 was observed at low doses where no IQ-mediated carcinogenic eŠects were observed. N-nitrosodiethylamine (NDEA) did not induce either GST-P positive foci or gene mutation at low doses. Concurrent administration of MeIQx and NDEA at no-eŠect doses did not induce GST-P positive foci. The no-eŠect doses for the biomarkers involved in the initiation and promotion stages of carcinogenesis suggest the existence of a threshold, at least a practical one, for the carcinogenic eŠects of these genotoxic carcinogens in the rat.
Lessons Learned from 40,000-animal
Cancer Dose-response Studies George S. Bailey (Oregon State University, USA) Dr. Bailey conducted two 40,000-animal cancer doseresponse studies. These experiments used rainbow trout, an animal model well suited to ultra low-dose carcinogenesis research, to explore dose-response down to a targeted 10 excess liver tumors per 10,000 animals (ED001*). In Study 1, 42,000 trout were fed 0-225 ppm dibenzo(def, p)chrysene (DBC) for four weeks, sampled for biomarker analyses, and returned to control diet for nine months prior to gross and histologic examination. Suspect tumors were conˆrmed by pathology, and resulting incidences were modeled and compared to the default EPA LED10** linear extrapolation method. Among nine statistical models explored, three were determined toˆt the liver data well-linear probit, quadratic logit, and Ryzin-Rai. Two-order extrapolations below the modeled tumor data predicted DBC doses producing one excess cancer per million individuals (ED10-6) that were 500-1500-fold higher than that predicted by thê ve-order LED10 extrapolation. In Study 2, a‰atoxin B1 (AFB1) was tested by using a similar design of Study 1 instead of DBC. Inclusion of allˆsh also yielded a sublinear dose-response, with slope 1.31 (95zCI 1.13-1.50), and an extrapolated ED 10 -6 17-fold greater than the LED10 default extrapolation. He concluded that two genotoxins with diŠering biological properties yielded ultra-low dose-response curves in the same animal model that are not compatible with the linear default as-sumption.
Urinary Bladder Carcinogenesis by DNA
Reactive and Non-Reactive Chemicals: Non-linearity's and Thresholds Samuel M. Cohen (University of Nebraska Medical Center, USA) Dr. Cohen categorized chemicals which can increase cancer risk into two groups: one can directly damage DNA and another can increase cell proliferation. He introduced that both types of chemicals have been shown to induce urinary bladder cancer in animal models and in humans. In animal models, cytotoxicity can be produced by formation of urinary solids or generation of reactive metabolites which are excreted and concentrated in the urine. In humans, arsenic is an example of a bladder carcinogen which acts by formation of reactive metabolites. The threshold is dependent on the presence in the urine of a cytotoxic concentration of the metabolite(s). The DNA reactive eŠect operates through formation of DNA adducts, and the dose response can be linear or non-linear, depending on metabolic activation processes. In contrast, for non-DNA reactive carcinogens, a threshold is present. Increased cell proliferation can occur either by cytotoxicity and regeneration, by direct mitogenesis, or by decreasing cell death. Dr. Cohen concluded that DNA reactive carcinogens have a non-linear dose response with respect to carcinogenicity and frequently have non-linear responses for DNA eŠects due to competing metabolic and repair processes. In contrast, non-DNA reactive carcinogens induce cancer as a consequence of a precursor toxic biologic eŠects which have thresholds. Dr. Kakinuma reported that current strategy for estimating the risk of genotoxic substances at low dose is a linear extrapolation based on the observed eŠects at high dose. It is generally considered that genotoxic carcinogens have no thresholds in exerting their potential for cancer induction. Here, she introduced her group's recent animal studies, which exhibited the existence of a threshold for carcinogenicities. They observed a threshold for both the N-ethyl-N-nitrosourea (ENU) and fractionated X-rays in induction of T-cell lymphoma in B6C3F1 mice. In addition, they found that ENU signiˆcantly increased point mutation frequency in a dose dependent manner, even below threshold dose for lymphomagenesis. Interestingly, co-exposure with subcarcinogenic dose of X rays decreased incidence of ENU-induced lympomas, suggesting that threshold of ENU mutagenesis could be in‰uenced by X-ray co-irradiation. Dr. Kakinuma concluded that threshold of ENU for lymphomagenesis is determined by the condition of thymic cells to be initiated and progressed into malignancy.
6. Exposure to Ethylating Agents: Where Do the Thresholds for Mutagenic/Clastogenic EŠects Arise?
Elmar Gocke (HoŠmann-La Roche Ltd, Switzerland) Dr. Gocke reported on the consequences of an accident in the production of tablets of a HIV medication (Viracept) leading to the presence of a low amount of EMS (ethyl methanesulfonate) as genotoxic contaminant. For alkylating agents like EMS it is generally assumed that the dose response for mutagenicity is linear-indicating that no`safe' dose does exist. The ingestion of the genotoxic contaminant, thus, may confer some genotoxic/carcinogenic risk to the patients. This issue triggered non-clinical studies where the dose response for mutation was analyzed after chronic dosing of mice with EMS. His group's studies with dose levels ranging from 1.25 to 260 mg/kg/day up to 28 days provided evidence that daily doses of up to 25 mg/kg/day did not induce any increase of mutations in the lacZ gene in the four organs tested (bone marrow, liver, GI tract, liver) or of micronuclei in bone marrow. Their investigations unambiguously demonstrated thresholded dose relations for mutagenic/clastogenic eŠects by EMS. The evidence was accepted by the authorities as su‹cient to show that the exposure to the contaminated Viracept tablets posed no risk to the patients. Theseˆndings have important implications for the risk assessment of low dose exposures to genotoxic agents, and should impact on impending new regulation, e.g., on the limitation of PGI's (potentially genotoxic impurities) in pharmaceuticals.
Oxidative Stress-induced Tumorigenesis in
the Small Intestine of Mutyh-deˆcient Mice: the EŠect of Low-level Exposure to KBrO 3
Teruhisa Tsuzuki (Kyushu University, Japan) MUTYH is a DNA glycosylase that excises adenine or 2-hydroxyadenine (2-OH-A) incorporated opposite either 8-dihydroguanine (8-oxoG) or guanine, respectively, thus considered to prevent G:C to T:A transversions in mammalian cells. Dr. Tsuzuki reported Mutyh-deˆcient mice showed a marked predisposition to spontaneous tumorigenesis in various tissues including intestines when examined at 18 months of age. The incidence of adenoma/carcinoma in the intestine signiˆcantly in-creased in Mutyh-deˆcient mice, as compared with wildtype mice. He also showed that the intestinal tumor susceptibility of Mutyh-deˆcient mice was further enhanced by treatment with KBrO3, a known oxidative renal carcinogen associated with 8-oxo-G accumulations. Oral administration of KBrO3 at a dose of 0.2z in drinking water dramatically increased the formation of intestinal tumors in Mutyh-deˆcient mice. Additionally, he reported a tumor-formation at a dose of 0.1z in the small intestines of Mutyh-deˆcient mice, but no tumor-formation was observed at a 0.05z. Based on theseˆndings, he concluded that cells are able to correctly repair oxidative DNA lesions resulting from exposures to a certain level of low doses of endogenous and exogenous chemicals with oxidizing property, and thus are less likely to be transformed to the neoplastic phenotype.
How Do Thresholds for Mutagenicity and
Clastogenicity Arise for DNA Damaging Agents?
George E. Johnson (Swansea University, U.K.) Dr. Johnson introduced prospective observations about thresholds for mutagenicity and clastogenicity arise for DNA damaging agents. There has been a recent shift by the scientiˆc and regulatory community, towards accepting genotoxic thresholds. Nevertheless, there are still many unanswered questions and the mechanisms responsible for`genotoxic tolerance' at low doses are wide ranging but poorly understood. For DNA reactive genotoxins, non-linear dose responses can arise from many diŠerent biological mechanisms. These include lack of bioavailability and nuclear exclusion, detoxiˆcation/activation, DNA repair and other homeostatic defense enzymes. He showed the results about the roles of DNA repair in genotoxic thresholds for alkylating agents and pro-oxidant chemicals. Speciˆc DNA repair enzymes have been shown to be upregulated by low dose alkylating agents, and knocking down speciˆc DNA repair enzymes in vitro alters the shape of the dose response, e.g., to EMS. Conversely, for pro-oxidants, he exhibited that antioxidant defenses and speciˆcally the presence of glutathione, are perhaps more important in genotoxic tolerance at low doses of pro-oxidants. Other mechanisms that impact on the dose response are linked to secondary eŠects such as dose fractionation and metabolic activity. Based on these observations, he concluded that ascertainment of mechanism is essential before genotoxic thresholds can be accepted. In health risk assessment of environmental contaminates, such as air pollutants, carcinogenic chemicals are generally categorized according to whether or not they are genotoxic. The potency of genotoxicity is determined by not only the reactivity of the chemical to DNA but also the protective system against chemical toxicity. This protective system is governed by processes such as phase I and II drug-metabolism, excretion, and DNA repair. Dr. Aoki's research focused on phase II drug-metabolizing enzymes, whose constitutive and inducible gene expression is regulated by the essential transcription factor Nrf2. The genotoxic potency of air pollutants under Nrf2-deˆcient conditions was examined by using diesel exhaust (DE) and benzo[a]pyrene (BaP) as model pollutants. After exposing mice to DE for 4 weeks, the levels of bulky-DNA adduct and 8-OHdG in the lungs of Nrf2-knockout (KO) mice were higher than those of Nrf2-bearing control mice. Intratracheal administration of BaP elevated the in vivo mutation frequency (MF) in the lungs of both Nrf2-KO and Nrf2-bearing control mice, but the increase in MF induced by BaP was enhanced in Nrf2-KO mice. These results indicate that the level of phase II-drug metabolizing enzymes is a determinant of the genotoxic potency of air pollutants such as DE and BaP.
Toxicity Testing Strategy Based on the Concept of the Threshold of Toxicological Concern (TTC)
Akihiko Hirose (National Institute of Health Sciences, Japan) Dr. Hirose introduced the concept of Threshold of Toxicological Concern (TTC). TTC is an exposure level below which there would be no appreciable risk to human health. The concept is practically useful to evaluate risk of a large number of chemicals such as those migrated from plastics of food containers, packaging and apparatus where only insu‹cient toxicity data are available. Regulatory authorities, i.e., U.S. Food and Drug Administration (FDA) and European Food Safety Authority (EFSA), and several industrial associations in Japan developed the guidelines for assessment of potential risk of food-contact materials based on the concept of TTC and the migration levels. In the guidelines, the lowest threshold level of exposure is 0.5 ppb (＝1.5 mg/person/day). No safety tests are required if the ex-posure levels are below it. This is based on the assumption that even genotoxic compounds have no adverse eŠects on humans below the level. The threshold value of 0.5 ppb is deduced from the carcinogenic potency database. Above 0.5 ppb but below 50 ppb, only in vitro genotoxicity tests are required. The level of 50 ppb is considered to be a threshold for non-genotoxic substances. Above 50 ppb but below 1 ppm, an in vivo genotoxicity test and two subchronic toxicity tests are additionally requested. However, scientiˆc bases for the higher thresholds of 50 ppb or 1 ppm are unclear. Therefore, Dr. Hirose is replacing the threshold values of 50 ppb and 1 ppm with exposure levels below which no toxicity is actually observable. The concept of TTC has been expanded for general toxicity endpoints (Kroes et al. 2000 (Kroes et al. , 2004 other than carcinogenicity. The concept may be helpful for establishment of thresholds for various toxicity indexes.
Closing Remarks
Shoji Fukushima (Japan Bioassay Research Center, Japan)
It has been accepted that no threshold for the genotoxic carcinogens exits in the risk assessment and management. However, this conclusion is based not on the scientiˆcally obtained data but on the hypothetical presumption. Therefore, to solve this problem, and to investigate whether the threshold for the eŠects of geno-toxic carcinogens exists or not, the accumulation of the scientiˆc data is very important. This is the 2nd International Symposium on Genotoxic and Carcinogenic Thresholds organized under the leadership of Dr. Nohmi. The aim of this Symposium, in line with the previous one, is the meeting of genotoxicity, carcinogenicity and otherˆeld researchers, who do not usually contact, and make them to dispute, thus to come closer to the solution of the problem concerning the threshold. Just I want to ask you, what is your opinion on the dispute at the Symposium? I feel that the contour of the top of mountain covered with very heavy clouds is now become clearer seen. However, not completely, therefore it is still necessary to coordinate our eŠorts to make it more and more clear. The future suggestions from the participants of the Symposium on the topic are very welcomed. Please do not hesitate to contact and support this researchˆeld for right resolution. At last, I would like to say my gratitude to the staŠ from the Department of Dr. Nohmi for the wonderful organization of the Symposium.
